Analysts’ Opinions Are Mixed on These Healthcare Stocks: BioMarin (NASDAQ: BMRN) and AbbVie (NYSE: ABBV)

By Carrie Williams

Analysts have been eager to weigh in on the Healthcare sector with new ratings on BioMarin (NASDAQ: BMRN) and AbbVie (NYSE: ABBV).

BioMarin (NASDAQ: BMRN)

Credit Suisse analyst Kennen MacKay maintained a Buy rating on BioMarin (NASDAQ: BMRN) yesterday and set a price target of $112. The company’s shares opened today at $92.45.

According to TipRanks.com, MacKay is a 5-star analyst with an average return of 17.1% and a 63.8% success rate. MacKay covers the Healthcare sector, focusing on stocks such as Five Prime Therapeutics, Akebia Therapeutics, and Puma Biotechnology.

Currently, the analyst consensus on BioMarin is Strong Buy and the average price target is $117, representing a 26.6% upside.

In a report issued on April 13, Cowen & Co. also reiterated a Buy rating on the stock with a $150 price target.
AbbVie (NYSE: ABBV)

Credit Suisse analyst Vamil Divan maintained a Hold rating on AbbVie (NYSE: ABBV) yesterday and set a price target of $60. The company’s shares opened today at $64.03.

According to TipRanks.com, Divan is a 4-star analyst with an average return of 4.6% and a 54.5% success rate. Divan covers the Healthcare sector, focusing on stocks such as Corvus Pharmaceuticals Inc, Alder Biopharmaceuticals, and Adamas Pharmaceuticals.

Currently, the analyst consensus on AbbVie is Moderate Buy and the average price target is $70.83, representing a 10.6% upside.

In a report released today, BMO Capital also reiterated a Hold rating on the stock with a $63 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.